Podcast appearances and mentions of Nathan H Fowler

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes.

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Go online to PeerView.com/HPR860 to view the entire program with slides. In this activity, an expert in B-cell lymphoma discusses updated efficacy and safety evidence on several new agent classes across a range of lymphoma settings, including B-cell receptor inhibitors, novel antibodies, Bcl-2 inhibitors, immunomodulators, and CAR-T therapy. In addition, this activity explores the role of these various therapeutic options in diseases such as FL, CLL, MCL, and DLBCL, and also reviews important safety and dosing information useful for clinical care. Upon completion of this activity, participants will be able to: Summarize updated efficacy and safety evidence on BCR inhibitors, apoptosis agents, next-generation antibodies, immunomodulators, CAR-T cell therapy, and other emerging strategies in different B-cell lymphoma settings, Employ regimens with novel components for the management of newly diagnosed or relapsed/refractory indolent and aggressive lymphoma, including diseases such as CLL, FL, MCL, or DLBCL, among others, Manage safety considerations in patients with B-cell malignancies who are receiving treatment with novel agent classes

Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL

Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL

Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL

Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL

Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL